Γ

SynBioBeta Speaker

Dong-Eun Chang

GFfermentech

Vice President

At HLB Genex & GF Fermentech, we specialize in advancing synthetic biology innovations from laboratory-stage concepts to scalable industrial production. Our work centers on enzyme engineering, strain optimization, and precision fermentation, supported by a 160 kL manufacturing infrastructure. Through an integrated CDMO platform, we help partners streamline the transition from R&D to commercial manufacturing, with strengths in advanced downstream processing, high-purity production, and LMO-certified operations. Our focus is on enabling the efficient and reliable market entry of complex enzymes and functional biomaterials.

Sessions Featuring

Dong-Eun

This Year

Lightning Talk

11:42 AM

-

11:46 AM

Biomanufacturing

Scaling the Future: Accelerating Enzyme Innovation and Biomaterial Commercialization

The true potential of synthetic biology is often bottlenecked by the leap from specialized lab research to cost-effective industrial production. HLB Genex & GF Fermentech are here to break that barrier. By integrating expert enzyme engineering and strain optimization with our total 160kL precision fermentation infrastructure, we provide a fast-track for bio-innovation.

Lightning Talk

11:42 AM

-

11:46 AM

Biomanufacturing

Scaling the Future: Accelerating Enzyme Innovation and Biomaterial Commercialization

The true potential of synthetic biology is often bottlenecked by the leap from specialized lab research to cost-effective industrial production. HLB Genex & GF Fermentech are here to break that barrier. By integrating expert enzyme engineering and strain optimization with our total 160kL precision fermentation infrastructure, we provide a fast-track for bio-innovation.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include